Science Translational Medicine highlights AI, imaging

Science Translational Medicine used its latest issue and online promotion this week to spotlight two translational themes: AI tools that sort breast cancer risk and imaging approaches aimed at detecting kidney fibrosis without relying only on biopsy. The journal’s own social post pointed readers to an AI risk model for breast cancer prevention and to next-generation imaging for renal fibrosis. (science.org) Those are separate research tracks, but they address a similar clinical problem. (science.org) Breast cancer prevention depends on identifying which patients are most likely to benefit from closer screening or preventive treatment, while chronic kidney disease care depends on measuring scar tissue early enough to track progression and response to therapy. (science.org) Science Translational Medicine has published work in both areas over recent years, including breast imaging-based risk models and noninvasive fibrosis imaging studies. ### What is the breast cancer AI model trying to do? A Science Translational Medicine paper on imaging-based breast cancer risk prediction described a model built from digital breast tomosynthesis, or DBT, screening exams to estimate short-term risk after a negative screen. (science.org) The authors said the goal was to use information already present in screening images to predict future late-stage and interval cancers and help guide clinical care. The model in that paper was developed from a nested case-control study drawn from 154,200 multiethnic women in the United States between 2014 and 2019, according to the article. In the left-out validation set, the paper reported discrimination performance for 1-year risk of 0.82, with 14% of women classified as high risk under U.S. (science.org) Preventive Services Task Force guidance and facing a risk 19.6 times higher than general risk. A related Science Translational Medicine commentary said more accurate mammography-based risk models could support both earlier detection and less overtreatment by matching screening intensity more closely to individual risk. (science.org) That article argued for risk-based guidelines rather than one-size-fits-all screening schedules. ### Why does that matter for prevention rather than just diagnosis? U.S. screening guidelines differ on when to start mammography, how often to repeat it and when to add supplemental imaging, the commentary said. Better risk stratification could affect who is offered intensified screening, MRI, chemoprevention or other preventive interventions. (science.org) The journal’s framing of the new issue appears to place the breast cancer paper in that prevention context. That is an inference from the journal’s description and from prior STM work on risk-based screening, rather than a new guideline recommendation. (science.org) ### What problem are kidney fibrosis imaging tools trying to solve? Kidney fibrosis is the buildup of scar tissue that drives chronic kidney disease progression, and current assessment often depends on biopsy or indirect functional measures. Science Translational Medicine has previously published imaging work showing that elastin-targeted magnetic resonance imaging could stage renal fibrosis noninvasively and monitor treatment response over time. (science.org) That elastin imaging study said elastin was minimally expressed in healthy kidneys but highly upregulated in progressive chronic kidney disease in mice, rats and humans. The authors reported that the imaging agent detected fibrosis in multiple mouse models and in fibrotic human kidneys, and captured treatment effects longitudinally. (science.org) ### Why is “next-generation imaging” a notable phrase here? Noninvasive imaging could give clinicians a repeatable way to quantify fibrosis burden instead of relying only on a single tissue sample. Reviews of kidney fibrosis diagnostics and therapeutics have said fibrosis-specific endpoints and better patient stratification are needed for trials and for development of antifibrotic therapies. (science.org) UCLA researchers, in a separate 2025 Science Translational Medicine study on type 5 collagen and kidney scarring, said they next want to develop a blood test to identify patients at greater risk for kidney failure. That work was not itself an imaging paper, but it shows the same push toward earlier measurement and stratification in renal fibrosis. (science.org) ### Where can readers check the underlying papers? Science Translational Medicine lists current and ahead-of-print articles through its table of contents feed on Science.org. The journal’s latest issue pages and article records are the primary place to verify which breast cancer and kidney fibrosis studies were highlighted this week. (sciencedirect.com) As of May 21, 2026, the journal’s feed available through Science.org shows current issue listings, while the social post cited in the briefing points readers to the highlighted breast cancer AI and kidney fibrosis imaging items. (science.org) (newsroom.ucla.edu)